Drug intelligence / Profile preview

lazuvapagon

Development stage: Phase 2
Lead developer: Sanwa Kagaku Kenkyusho
Modality: Small Molecules
Administration: Oral[6]

Overview

Lazuvapagon (SK-1404) is a small molecule vasopressin V2 receptor agonist developed for the treatment of nocturia due to nocturnal polyuria. It acts by promoting water reabsorption in the renal collecting ducts, thereby reducing urinary output (antidiuresis), mimicking the action of endogenous antidiuretic hormone arginine vasopressin. Lazuvapagon demonstrates rapid absorption and elimination and is being investigated for its efficacy and safety in clinical trials targeting urogenital disorders such as nocturia[1][3][5][6].

Other names: lazuvapagonSK-1404SK1404SK 1404KRP-N118KRP-N-118KRP-N 118

Targets

AVPR2 (Arginine vasopressin V2 receptor)

Beyond the preview

Go deeper on lazuvapagon.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lazuvapagon.

Explore the full profile